Background: Aspects of impulsivity have been implicated in the development, or maintenance, of alcohol use disorder (AUD). The brain dopamine system is implicated in both reward processing/memory (typically subcortical) and in brain inhibitory control mechanisms (typically cortical). Using a validated clinical laboratory paradigm, the dopamine/serotonin "stabilizing" drug, aripiprazole was evaluated in non-treatment-seeking AUD individuals based on their level of impulsivity/self-control.
A LCOHOL ABUSE AND dependence affect over 18 million Americans (Grant et al., 2004) and constitute one of the highest burdens of illness worldwide (Rehm et al., 2014) . Data suggest that the peak prevalence of alcohol use disorders (AUDs) occurs in the early 20s (Grant et al., 2016) , and while many individuals no longer meet diagnostic criteria as they grow older, others maintain a trajectory of increasing alcohol consumption and eventually seek treatment in their 30s and 40s. A number of studies have tried to evaluate what characteristics distinguish those who drink heavily at an early age and/or go on to develop AUDs. One characteristic that has received increasing attention is broadly defined as "impulsivity." This multidimensional construct can be defined and measured in a variety of ways; recent data support a tripartite latent structure comprised of impulsive choice, impulsive action, and impulsive personality traits (MacKillop et al., 2016) . One subdimension of impulsivity that may hold special relevance for addictive behavior is self-control, which can be defined as the ability to inhibit prepotent responses and regulate behavior (de Ridder et al., 2012) . In AUDs, drinking becomes a prepotent response, and impaired self-control may thus be a particular risk factor for the progression of these disorders (Leeman et al., 2014) .
It has been postulated that high impulsivity significantly contributes to the development of addiction (Bechara, 2005; Perry and Carroll, 2008; Verdejo-Garcia et al., 2008) and plays a decisive role in the switch to compulsive drug use (Belin et al., 2008) . Individuals (particularly adolescents and young adults) who are more impulsive drink more heavily and are more likely to have, or progress to, an AUD (von Diemen et al., 2008; Dougherty et al., 2004; Rubio et al., 2008; Simons et al., 2004) . Impulsive individuals have poor decisional balance (Wilcox et al., 2014) and are more likely to accept a smaller immediate reward than a later, more lucrative, reward. Therefore, impulsive individuals might be more likely to choose alcohol when presented with an opportunity to drink even though a "price" would have to be paid in the future (e.g., hangover, missing work, spouse's anger). It is also possible that impulsive individuals will have more craving for alcohol than nonimpulsive individuals, thus being unable to resist alcohol cue-elicited urges to drink (Papachristou et al., 2012) ; something we have indirectly observed in our preliminary studies (Voronin et al., 2008) . Individuals with higher impulsivity also have more difficulty ceasing drug/alcohol use and relapse more quickly if they do (Bowden-Jones et al., 2005; Perry and Carroll, 2008) , and co-occurring heavy alcohol use and impulsivity leads to increased mortality over time (Blonigen et al., 2011) . Thus, impulsivity is a significant risk factor for the development and progression of AUDs.
Given these clinical observations, it is not surprising that impulsivity has been assessed as an intermediate phenotype for addiction (Dick et al., 2010; Moffitt et al., 2011) and has attracted study of its neurochemical, neuroanatomical, and genetic underpinnings (Cardinal, 2006; Congdon and Canli, 2005; Kreek et al., 2005) . In animal studies, new models of impulsive behavior have given support to older assumptions that the brain dopamine, and to some extent the brain serotonin, systems are likely involved (for review, see Jentsch et al., 2014) . Trait-impulsive rats self-administer cocaine to a significantly larger degree than nonimpulsive rats and, importantly, have lower dopamine D2 and D3 receptor availability in the nucleus accumbens (Dalley et al., 2007) . Similarly, rats lacking D2 receptors also administer cocaine in larger amounts (Caine et al., 2002) while chronic stimulant users show a down-regulation in dopamine release and D2/D3 receptor availability (Ashok et al., 2017) . Of note, either reduction or blockade of D3 receptors reduces alcohol intake in rodents (Bahi and Dreyer, 2014; Thanos et al., 2005) or alters reward processing in humans (Murphy et al., 2017) . Interestingly, the D3 receptor has been suggested to play a more salient role in motivated alcohol/drug responding in the context of higher environmental contingencies (for review, see Le Foll et al., 2005) . While these studies implicate the dopamine system in the reward pathway as mediating a role between impulsivity and reward seeking, it is also clear that dopamine plays a major role in cortical function, response inhibition, and possibly some aspects of impulsivity in humans (for review, see Cardinal 2006; Congdon and Canli 2005) . A number of lesion, stimulation, and pharmacological studies done in rodents indicate that the nucleus accumbens and orbitofrontal cortical areas, in particular, play a large role in choice of delayed versus immediate reinforcement (one aspect of impulsive responding) and that dopaminergic transmission plays a crucial role in this effect (for review, see Cardinal 2006; Winstanley 2007) . It has also been hypothesized, based on available data, that either too much or too little dopamine system function in these crucial brain areas might lead to impulsive behavior and/or responding (Winstanley, 2007) . Other brain areas implicated in animals and humans are inferior frontal cortex, dorsolateral cortex, anterior and posterior cingulate, and dorsal striatum. It should be noted that many of these regions are also activated by substance cues, including alcohol cues or the drugs themselves. For instance, there is direct relationship between dopamine receptor availability in the ventral striatum and alcohol craving, cue activation of the medial prefrontal cortex (Heinz et al., 2004) , and level of intoxication (Yoder et al., 2005) . In addition, at least for alcohol, direct effects on frontal areas might increase risk of impulsive choices (Crews and Boettiger, 2009) . For instance, an electrophysiological study in humans showed that alcoholics had reduced frontal lobe activity and that reduced frontal lobe activity correlated with impulsivity traits as measured by the Barratt Impulsiveness Scale (Chen et al., 2007) . There is also considerable work (primarily in animals) implicating the brain serotonin system in impulsive behaviors (for review, see Kirby et al., 2011; Jentsch et al., 2014) including effects of serotonin depletion on worsening action inhibition, waiting, and delayed risk decision making. Conversely, increasing serotonin does the opposite. Importantly, there is a suggestion of opposing actions of 5HT2A and 5HT2C receptors such that antagonism of 5HT2A receptors reduces various aspects of impulsivity while the opposite occurs with 5HT2C antagonism.
Given the possible link between impulsivity/self-control and brain/serotonin pathways, as well as the role dopamine in particular plays in alcohol reward and reinforcement (Volkow et al., 2007) , medications with dopaminergic effects might be useful for treating AUDs. One such medication is aripiprazole, a putative dopamine stabilizer medication. Aripiprazole has been approved by the Food and Drug Administration for the treatment of schizophrenia (DeLeon et al., 2004; Marder et al., 2003) , bipolar disorder (Keck et al., 2006) , and, most recently, as an adjunct to treat depression. Its pharmacological profile differs from other dopamine antagonists. It acts either as a primary brain dopamine system stabilizer (Lawler et al., 1999) , or potentially more universally "stabilizes" dopamine-serotonin balance (Burris, 2002) perhaps by its serotonin 5HT2A antagonism effects. However, aripiprazole has been postulated to work primarily as a partial dopamine agonist in that it reduces dopamine actions when dopamine concentrations are high, while producing dopamine agonist-like effects in the absence, or at low concentrations, of dopamine. This might occur directly by reducing dopamine effects at postsynaptic receptors, or, indirectly, by presynaptic dopamine receptor blockade (thereby removing the inhibition of dopamine transmission). The net effect of either of these mechanisms is to keep dopamine "balanced." The clinical utility of this unique pharmacology is that aripiprazole behavioral effects could be obtained while off-target effects such as extrapyramidal effects, or tardive dyskinesia might be minimalized (Marder et al., 2003) . In the nucleus accumbens, aripiprazole reduces dopamine release at higher doses but increases prefrontal dopamine release at lower doses (Li et al., 2004) . However, its elevation of prefrontal dopamine appears specific, as serotonin and norepinephrine do not seem to be increased (Zocchi et al., 2005) . This unusual pharmacological profile might be particularly useful in the treatment of addiction, either by reducing reward saliency, or by increasing cortical efficiency-potentially leading to more "self-control" and less impulsive drinking behavior. Aripiprazole's 5HT2A antagonist effects could also reduce impulsive responding in humans as postulated by animal studies (Jentsch et al., 2014) .
Aripiprazole was found to reduce alcohol use in animals (Ingman et al., 2006) and, in a clinical laboratory paradigm, to decrease the euphoric effects of alcohol in humans . While high-dose side effects limited interpretation of the results, a large U.S. clinical trial indicated that, while aripiprazole did not promote abstinence, it significantly reduced drinks per drinking day and alcohol dependence symptoms, ameliorated many of the effects of alcohol consumption, and normalized a biological marker (%CDT) of heavy alcohol use . Recent reviews have suggested that, while aripiprazole might be useful for the treatment of AUDs, there are not enough data to draw firm conclusions (Kishi et al., 2013; Litten et al., 2016; Martinotti et al., 2016) .
While clinical trials are expensive and take time to conduct, especially when evaluating medication effects on AUD endophenotypes, clinical laboratory studies can often provide an initial signal of medication efficacy that might inform clinical trial development (Ray et al., 2010) . We have developed a clinical laboratory paradigm to evaluate various medications, including naltrexone (Anton et al., 2012; Drobes et al., 2003) , nalmefene (Drobes et al., 2003) , and gabapentin (Myrick et al., 2007) . We previously evaluated the effects of aripiprazole in this paradigm and found that it reduced alcohol consumption and alcohol-induced stimulation (Voronin et al., 2008) . Importantly, post hoc analyses indicated that aripiprazole reduced drinking only among individuals who rated themselves low on the self-control subscale of the Barratt Impulsiveness Scale (BIS-11) (Patton et al., 1995) . To our knowledge, no other data are reported on this intriguing finding, which might suggest a more "targeted" pharmacotherapeutic use for aripiprazole in those with AUDs.
The purpose of the current study was to replicate and extend our previous findings in a prospective study. To accomplish this, non-treatment-seeking individuals meeting DSM-IV criteria for alcohol dependence, who were either low and high in trait impulsivity/self-control, were randomized to aripiprazole or placebo in a double-blind fashion and evaluated for effects on drinking and relatedbehaviors using the same subacute natural drinking and alcohol self-administration paradigm as used previously (Voronin et al., 2008) . Specifically, we hypothesized that (i) aripiprazole would reduce drinking under natural conditions and/or in a bar laboratory setting and (ii) those with more trait impulsivity and/or less self-control would show a greater response to aripiprazole compared to placebo. Secondarily, we wanted to explore the effect of aripiprazole versus placebo on alcohol-induced stimulation and sedation, and also whether impulsive individuals would drink more slowly while on aripiprazole compared to placebo.
MATERIALS AND METHODS

Participants
Between April 2011 and December 2015, 137 non-treatmentseeking alcoholics between the ages of 21 and 40, recruited from ads in newspapers and social media, were screened for this study and 99 who met DSM-IV criteria for alcohol dependence (American Psychiatric Association, 1994) were randomized into the double-blind protocol.
Exclusion criteria were as follows: current DSM-IV criteria for nonalcohol substance dependence (excluding nicotine) by verbal report and urine drug screens, other major DSM-IV Axis I disorders, psychoactive medication or substance use (except marijuana) in the past 30 days or a positive urine drug screen, current suicidal or homicidal ideation, past history of alcohol-related medical illness, liver enzymes ≥2.5 times above normal, or significant health problems.
Baseline Assessment Procedures
The Medical University of South Carolina Institutional Review Board approved this study, and subjects signed informed consent. After initial phone screening and informed consent, further evaluation was done utilizing a demographic form, the Structured Clinical Interview for DSM-IV Axis I disorders (First et al., 1997) , the timeline follow-back interview (TLFB) (Sobell et al., 1988) to quantify drinking during the preceding 90 days, the BIS-11 (Patton et al., 1995) , the Obsessive-Compulsive Drinking Scale (OCDS) (Anton et al., 1996) , and the Alcohol Dependence Scale (ADS) (Skinner and Horn, 1984) . Finally, a urine drug screen, blood tests for health screening, and a physical examination were conducted. DNA from blood white cells was collected for genetic analysis (data will be reported separately).
Randomization and Medication Dosing
Participants who passed all screening and eligibility criteria were stratified into high and low impulsivity groups on the basis of their BIS-11 scores. In our previous work among non-treatment-seeking individuals with alcohol dependence (Anton et al., 2012; Voronin et al., 2008) , the median BIS-11 score was 68 (about 10 points higher than age/sex matched social drinkers at our site), consistent with other reports of greater impulsivity among younger alcoholdependent individuals (von Diemen et al., 2008) . Thus, the "high" impulsivity group comprised those participants with a BIS-11 score ≥ 68, and the "low" group those participants with a score ≤ 67. Individuals within each impulsivity strata were further urn-randomized, based on sex and smoking status, to receive aripiprazole (5 mg on Day 1, 10 mg on Days 2 to 3, and 15 mg on Days 4 to 8) or identical placebo capsules in a blinded fashion. All study medications were taken each morning from a blister pack and administered in identical standard gel caps with 25 mg riboflavin added. The final dose level of aripiprazole (15 mg) was chosen based on the putative minimal effective dose in schizophrenia and mania, and low enough to avoid the extensive side effects observed in a multisite AUD study . It also showed some efficacy in reducing heavy drinking in a 14-day subacute observation study in our hands (Myrick et al., 2010) . The titration schedule was chosen to replicate our previous work (Voronin et al., 2008) . The last dose of aripiprazole was always taken in front of research personnel at the same time prior to lunch and the bar laboratory procedure (below) in order to (i) ensure compliance and to standardize food ingestion effects on absorption and (ii) to ensure that the time between ingestion and priming drink was standardized at peak aripiprazole concentration 3 to 5 hours after dosing (Mallikaarjun et al., 2004) .
Experimental Procedures and Outcome Assessments
During medication dosing, participants were given no explicit instructions regarding their drinking behavior for Days 1 to 6 but were required to abstain completely on Day 7 and the morning of Day 8. On Day 7, subjects were assessed for alcohol withdrawal using the Clinical Institute Withdrawal Assessment for AlcoholRevised (CIWA-Ar) (Sullivan et al., 1989 ) and a urine sample was collected to ascertain riboflavin levels (based on quantitative spectrofluorometric assay) for medication compliance. The majority of the CIWA-Ar scores were 0 (72% of subjects), and 97% were below 5. Drinking over the previous 6 days was assessed with the TLFB. On that evening, they underwent a functional magnetic resonance imaging (fMRI) alcohol cue-reactivity paradigm (similar to Myrick et al., 2010) , which will be reported separately.
On Day 8 of study medication, participants completed a 21-item side-effect checklist, ingested the last dose of study medication under observation at 11:30 AM, and 30 minutes later were provided a standard caloric lunch (weight-and gender-adjusted). At 2:00 PM, they consumed a standard dose of spirits (vodka, gin, rum, or bourbon) calculated to achieve a breath alcohol concentration (BAC) level of 0.02 to 0.03 g/dl (Watson, 1989) . The drink was 1 part spirits diluted in 3 parts fruit juice (both of the subject's choosing) and consumed over 5 minutes. Serial BAC measurements were done at 10, 20, and 30 minutes after drink consumption. At each of these time points, the Biphasic Alcohol Effects Scale (BAES) (Martin et al., 1993) was administered to assess stimulation and sedation. At 40 minutes after the initial drink, the curtain in the bar laboratory was opened to reveal bar-like cues and participants were brought the first tray of 4 "mini-drinks" (each consisting of one-half the alcohol consumed in the initial drink and calculated to produce a BAC of 0.015 g/dl) and were told that they could purchase (see below) and consume as many as they desired over the next hour period. In a second-hour period, another 4 "mini-drinks" were made available for consumption. A BAC assessment was done at the end of this 2-hour drinking period. As per our previous paradigms and consistent with that of O'Malley and colleagues (2002), participants were given a "bar credit" of $16, with which they could purchase mini-drinks (as a cost of $2 each) to assess alcohol consumption in the context of an alternative reinforcer. Any money from the bar credit that participants did not use to purchase drinks was given to them the following day. Participants had access to 1 bag of potato chips (28.3 g/bag) per tray to simulate a normal bar environment, and water was also provided. The number of drinks consumed over the 2-hour bar laboratory period was the main dependent variable for analysis.
After the procedure, participants remained until 10:00 PM and were given dinner and could read, listen to music, or watch videosbut were also provided educational materials regarding alcohol effects to motivate a change in drinking behavior. A breathalyzer reading below 0.02 g/dl was required at departure and they were driven home by a friend or taxi. The following day, a counseling session was given to educate participants about alcohol harm and to increase motivation to reduce drinking or seek treatment. Participants were compensated $360 for their participation, plus any unspent money from their bar credit.
Sample Size, Outcome Variables, and Statistical Approach
The effect size from our previous work (Voronin et al., 2008) for the interaction between aripiprazole and BIS-11 self-control on drinks per day during the 6-day natural observation period indicated that a sample size of 25 subjects per group (total N = 100) would yield 85% power to detect an interaction of the same magnitude (equivalent 2-group d = 0.6). While not significant in our previous study, power for detecting an interaction between BIS-11 group and medication for the limited access drinking paradigm was based on our previous effect size (Cohen's d = 0.78 for aripiprazole over placebo); assuming the aripiprazole effect was only present in the low-self-control group, power to detect the interaction was greater than 50% with a sample size of 100.
The main a priori defined dependent variables were (i) drinking under natural conditions (drinks per day during the 6 days prior to the fMRI and bar laboratory experiment) and (ii) total drinks consumed after the priming drink in the bar laboratory paradigm. Using SPSS v. 23 (IBM Corporation, Armonk, NY), the general linear model (GLM) was used to test the effects of medication, BIS-11 group (high vs. low), and their interaction on these drinking variables. Because our previous work (Voronin et al., 2008) found an interaction between aripiprazole and the BIS-11 self-control subscale, this interaction was also examined; a median split on this subscale score (median = 13) was used to divide participants into highand low-self-control groups. For the analysis of drinking under natural conditions, baseline drinks per day was covaried; for the analysis of bar laboratory drinking, baseline drinks per drinking day was covaried. There were also 4 exploratory analyses. The first used the GLM to evaluate the interactions between continuously distributed total BIS-11 and BIS-11 self-control scores and medication group on bar laboratory drinking. The second used the GLM to evaluate the interaction between BIS-11 self-control quartiles and medication group on bar laboratory drinking. The third used the GLM to examine the effects of medication, BIS-11 group, and their interaction on the subjective effects of the priming drink (BAES stimulation and sedation). Finally, the fourth used Cox proportional hazard regression (conditional risk set model in Stata v. 13; StataCorp LLC, College Station, TX) to evaluate the effects of medication, BIS-11 group, and their interaction on latency to drink (time between drinks) in the bar laboratory. This model tests the difference in survival times between multiple events, conditioned on the existence of these events. Because there was relatively little drinking from the second tray of drinks in the high BIS/aripiprazole group, only the first tray (up to 4 drinks) was used for the latency to drink analysis.
RESULTS
Demographics and Drinking Variables
Of the 99 individuals randomized to study medication, 4 individuals did not progress to the alcohol ingestion paradigm (1 was lost to follow-up, 1 was incarcerated, 1 sustained a concussion in a car accident as a passenger, and 1 had a positive BAC on Day 7). That left 95 evaluable participants (47 on aripiprazole and 48 on placebo), whose baseline demographics and drinking characteristics are provided in Table 1 . By chance, baseline drinking was greater in the aripiprazole group than the placebo group; however, baseline drinking did not significantly differ across all 4 impulsivity/ medication groups. ADS and OCDS scores suggested mildmoderate AUD severity and did not significantly differ between groups. BIS-11 scores also did not significantly differ, as groups were a priori stratified as a function of this variable.
Drinking Under Natural Conditions
There were no significant main effects of BIS-11 group, F(1, 90) = 0.74, p = 0.39, BIS-11 self-control group, F(1, 90) = 0.11, p = 0.74, or medication, F(1, 90) = 1.30, p = 0.26, on drinks per day under natural conditions, nor were there significant interactions between BIS-11 group and medication, F(1, 90) = 0.60, p = 0.44, or BIS-11 self-control group and medication, F(1, 90) = 0.51, p = 0.48, on this variable (Fig. 1) .
Bar Laboratory Drinking
There were no significant main effects of medication or BIS-11 score nor an interaction between these factors on the decision to drink; 75% of low BIS/placebo, 87% of low BIS/ aripiprazole, 80% of high BIS/placebo, and 83% of high BIS/aripiprazole subjects opted to drink. While there was no significant main effect of BIS-11 group on the total number of drinks consumed in the bar laboratory, F(1, 90) = 0.095, p = 0.76, there was, however, a significant main effect of medication, F(1, 90) = 4.32, p = 0.041, partial g 2 = 0.046, such that individuals who received aripiprazole (M = 4.6 drinks, 95% CI = 3.7 to 5.4) drank less than those who received placebo (M = 3.3 drinks, 95% CI = 2.5 to 4.2). There was no significant interaction of BIS-11 group and medication on drinking, F(1, 90) = 1.92, p = 0.165 (Fig. 2) . However, the interaction between BIS-11 self-control group and medication was significant, F(1, 90) = 4.64, p = 0.034, partial g 2 = 0.049, such that, among participants with low self-control, those who received aripiprazole (M = 2.7 drinks, 95% CI = 1.5 to 3.9) drank less than those who received placebo (M = 5.3 drinks, 95% CI = 4.1 to 6.5), while among those with high self-control, drinking was similar in both medication groups (aripiprazole M = 3.8 drinks, 95% CI = 2.7 to 4.9; placebo M = 3.9 drinks, 95% CI = 2.8 to 5.0) (Fig. 3) . Essentially, participants with low self-control who received aripiprazole consumed about 50% less alcohol than those who received placebo.
Two further analyses were conducted to evaluate the interaction between continuous BIS-11 total and self-control scores and medication group. Covarying for sex and smoking status, which were significant independent predictors of bar laboratory drinking in these models, the interaction between total BIS-11 score and medication, F(1, 89) = 2.80, p = 0.098, partial g 2 = 0.031, and the interaction between self-control score and medication, F(1, 89) = 2.62, p = 0.11, partial g 2 = 0.029, were not significant; however, both were in the same direction as the analyses that used the mediansplit variables (i.e., aripiprazole, relative to placebo, reduced drinking more among subjects with greater impulsivity/less self-control). Also, to better understand how specific level of self-control affected the medication effect, self-control scores were grouped by quartile (Table 2) . Covarying for baseline drinks per drinking day, the omnibus interaction between self-control quartile and medication was significant, F(3, 86) = 3.08, p = 0.032, partial g 2 = 0.097. Post hoc analysis indicated that the simple effect of medication on bar laboratory drinking was significant only among individuals in the highest quartile (lowest self-control), F(1, 86) = 10.15, p = 0.002, partial g 2 = 0.11. There was no significant main effect of medication on latency to drink in the bar laboratory, but the main effect of BIS-11 group approached significance (B = À0.34 [SE = 0.20], 95% CI = À0.74 to 0.053, z = À1.70, p = 0.089), such that more impulsive participants tended to have shorter latencies between drinks. The interaction between medication and BIS-11 group was significant (B = 0.61 [SE = 0.30], 95% CI = 0.014 to 1.20, z = 2.01, p = 0.045), such that, among participants with greater impulsivity, those treated with aripiprazole, relative to placebo, had longer latencies between drinks, while among participants with lower impulsivity, there was no difference between aripiprazole and placebo (Fig. 4) . The interaction between medication and BIS-11 self-control group on latency to drink was in the same direction as the medication by BIS-11 group interaction but not significant (B = 0.47 [SE = 0.30], 95% CI = À0.012 to 1.06, z = 1.57, p = 0.12).
Participants who received aripiprazole had slightly, but significantly, higher peak BACs after the priming drink than those who received placebo (aripiprazole M = 0.025 [SD = 0.0013] g/dl; placebo M = 0.022 [SD = 0.0013] g/dl; F(1, 93) = 8.78, p = 0.004). However, both the main effect of medication, F(1, 89) = 4.69, p = 0.033, partial g 2 = 0.05, and the interaction with BIS-11 self-control group, F(1, 89) = 4.55, p = 0.036, partial g 2 = 0.049, on bar laboratory drinking remained significant when peak BAC was covaried. The The omnibus interaction between Barratt Impulsiveness Scale (BIS) self-control quartile and medication was significant, F(3, 86) = 3.08, p = 0.032. Figures are estimated marginal means AE standard errors, covarying for baseline drinks per drinking day.
Bolded values indicate significance.
effect of peak BAC on latency to drink approached significance (B = À0.028 [SE = 0.015], z = À1.86, p = 0.063), such that participants with higher BACs had shorter latencies to drink, but the interaction between medication and BIS-11 group remained significant when peak BAC was covaried (B = 0.73 [SE = 0.31], 95% CI = 0.012 to 1.35, z = 2.33, p = 0.020).
Subjective Effects of Alcohol
There were no significant main effects or interactions of BIS-11 group, BIS-11 self-control group, or medication, on peak BAES stimulation after the priming drink. However, aripiprazole caused more sedation after the priming drink (M = 11.8, 95% CI = 8.9 to 14.6) than placebo (M = 6.0, 95% CI = 3.2 to 8.8), F(1, 90) = 8.14, p = 0.005, partial g 2 = 0.083, but this was not modified by BIS-11 group. Importantly, covarying peak sedation did not influence our main finding of the BIS-11 self-control by medication interaction on bar laboratory drinking that remained significant, F(1, 89) = 4.45, p = 0.038.
Compliance and Reported Adverse Effects
Based on Day 7 riboflavin levels, approximately 75% of participants were judged adherent with study medication, with no significant difference between medication groups. Table 3 details the adverse effects reported by individuals taking aripiprazole compared to placebo. Trouble sleeping, daytime sleepiness, and low energy were reported significantly more frequently in the aripiprazole group, with some effects reported as severe. Irritability, trouble concentrating, nausea/vomiting, dizziness, and difficulty reaching orgasm were also reported significantly more frequently in the aripiprazole group, but most of these effects were reported as mild to moderate. It should be noted that no participant discontinued medication due to adverse events. Also, prestudy presence or absence of a complaint was not taken into account in this analysis. Given that more adverse events were reported by those taking aripiprazole, we conducted a sensitivity analysis by including the presence or absence of each of the above side effects in an analysis examining the main effect of medication on bar laboratory drinking. Next, the effects that reduced the medication effect below statistical significance (daytime sleepiness, low energy, dizziness, and difficulty reaching orgasm) were entered together into a final analysis examining their impact on our major finding of the interaction between BIS-11 self-control group and medication group on bar laboratory drinking. That interaction remained significant, F(1, 86) = 4.91, p = 0.029, partial g 2 = 0.054, when these adverse events were covaried, suggesting that their presence was unrelated to the superior effect of aripiprazole in reducing bar laboratory drinking among individuals with low self-control.
DISCUSSION
We previously reported (Voronin et al., 2008) in a small exploratory study that aripiprazole reduced drinking both under subacute natural conditions and in a bar laboratory paradigm and that some of these effects were most evident in those with low self-control, as measured by the BIS-11. This work extends these findings in a larger experiment in which participants were prospectively randomized to aripiprazole or placebo based on their level of impulsivity (BIS-11 score). While aripiprazole did not significantly affect drinking during the natural observation period, after a priming drink in the more controlled paradigm of the bar laboratory, individuals on aripiprazole chose to drink less than those on placebo. Importantly, consistent with our prior work, the aripiprazole effect on drinking was most evident among those with low trait self-control, especially in those with the most extreme low self-control scores. Further, aripiprazole also increased time between drinks among individuals with high trait impulsivity. It should be noted that in this Fig. 4 . Mean time to first sip (min) of successive drinks from the first tray of free-choice drinks as a function of Barratt Impulsiveness Scale (BIS-11) scores and medication. Brackets indicate the number of participants in each group who drank that number of drinks. The interaction between BIS-11 group and medication on latencies between drinks was significant (p < 0.05), such that aripiprazole, relative to placebo. Increased latencies between drinks among high BIS, but not low BIS, subjects.
paradigm, individuals were forced to choose between immediate (alcohol) and delayed (money) rewards. As such, the paradigm tests the ability to inhibit an expected immediate rewarding choice. The brain dopamine system has been implicated both in reward perception and in modulating inhibitory responding (Volkow et al., 2007) . For instance, alcohol and alcohol cues increase dopamine release and activity in both animal and human ventral striatum (Boileau et al., 2003; Oberlin et al., 2013) and modification of this effect could influence alcohol choice, drinking, and craving (Myrick et al., 2010) . On the other hand, in other brain areas (e.g., prefrontal, orbital frontal) the dopamine system might play a separate and unique role in contextual appraisal and inhibition of prepotent or salient responses (for review, see Cardinal 2006; Congdon and Canli 2005) . Also, while it has been observed that alcohol acutely increases synaptic dopamine in both ventral striatum (Gonzales et al., 1998) and prefrontal cortex (Schier et al., 2013) , chronic alcohol and substance use can lead to a hypodopaminergic state (Koob, 2003) . Given this apparent dichotomy, an agent like aripiprazole that putatively "stabilizes" or "normalizes" dopamine transmission could positively modulate different brain areas, to affect drinking behavior. However, we cannot completely rule out either a main or partial contribution of aripiprazole's 5HT2A antagonism. Possibly, it is the combination of aripiprazole effects on the dopamine and serotonin systems that is most important.
In the current study, aripiprazole did not largely impact drinking under natural conditions, in which participants, who were nontreatment seeking, had no motivation to drink less. This finding differed from our previous work. As it is likely that drinking under natural conditions is more variable (because of social influences, motivation, medication compliance, etc.), lack of congruence across studies might be expected. However, aripiprazole did impact the choice to drink under a forced choice reward paradigm. Consistent with its major impact being on choice/inhibition rather than reward saliency, it appeared to work mostly among those who rated themselves a priori as being impulsive and/or most likely to have low self-control. Impulsivity and self-control are overlapping but dissociable constructs; in the current study, total BIS scores were strongly (r = 0.85) but not perfectly correlated with self-control scale scores. One proposed distinction between the two is that self-control reflects the ability (or lack thereof) to employ a "top-down" regulatory strategy, while impulsivity reflects the extent to which "bottom-up" impulses are generated (Duckworth and Kern, 2011) . This distinction is perhaps consistent with selfcontrol's moderating influence on aripiprazole's effect on the choice to consume more drinks (arguably a behavior reflecting a top-down decisional process), and impulsivity's moderating influence on aripiprazole's effect on the time between drinks (arguably a behavior reflecting a bottom-up urge). However, further exploration of the manner in which these personality traits, as well as other measurements of both impulsivity and self-control, may impact medication response is warranted.
The clinical implications of these findings need to be further elaborated and tested. For instance, in a large controlled double-blind study, aripiprazole did not have a significant effect on abstinent days but did show some reduction in drinks per day and other aspects of the AUD spectrum . Neither impulsivity nor self-control was measured in that study; these constructs might have been usefully employed to evaluate differential treatment effectiveness. Future clinical trials might use the relatively easy measurement of impulsivity and self-control provided by the BIS-11 or other personality inventories to select individuals to treat with aripiprazole. If the interaction of aripiprazole with low self-control is further replicated, it might be a useful pharmacotherapy paired with cognitive behavioral therapy or other approaches that encourage individuals to avoid or postpone drinking when tempted by cues or to substitute other behaviors for alcohol consumption. Those with lower self-control might particularly benefit from aripiprazole or other dopamine stabilizer/acting agents during such treatment attempts. Although these data are consistent with our previous findings (Voronin et al., 2008) , several factors limit their interpretation. Both studies employed a specific clinical laboratory paradigm and enrolled non-treatment-seeking individuals who were compensated for their participation. It is not clear whether these findings extend to more severe treatment-seeking individuals. In addition, the dose of aripiprazole used (15 mg), while moderate, might still have been higher and titrated more rapidly than needed in clinical settings. There were clear differences in the number of adverse effects reported by those on aripiprazole compared to placebo but these did not seem to influence adherence or the final results. Perhaps lower doses, titrated more slowly, might be as efficacious and more tolerable in clinical settings. While these data suggest that aripiprazole should not be considered for general AUD treatment, they do suggest those with more trait impulsivity (admittedly a limited number of all AUD individuals) might benefit from it.
In summary, in a large subacute natural drinking and bar laboratory paradigm, aripiprazole was effective in reducing alcohol consumption, but only when participants were forced to choose whether to drink in the context of a competing reward. Aripiprazole reduced the number of drinks consumed in this context the most among participants who rated themselves as having low self-control, and increased the amount of time between drinks the most among those with high impulsivity. As such, aripiprazole and other medications might be further evaluated for this population, perhaps leading to greater personalized pharmacotherapy for AUDs in the future.
